EA021464B1 - Производные индол-пиридона, обладающие ингибиторной активностью в отношении киназы 1, содержащая их фармацевтическая композиция и их применение - Google Patents

Производные индол-пиридона, обладающие ингибиторной активностью в отношении киназы 1, содержащая их фармацевтическая композиция и их применение Download PDF

Info

Publication number
EA021464B1
EA021464B1 EA201001197A EA201001197A EA021464B1 EA 021464 B1 EA021464 B1 EA 021464B1 EA 201001197 A EA201001197 A EA 201001197A EA 201001197 A EA201001197 A EA 201001197A EA 021464 B1 EA021464 B1 EA 021464B1
Authority
EA
Eurasian Patent Office
Prior art keywords
carboxylic acid
oxo
title compound
pyrazole
amide
Prior art date
Application number
EA201001197A
Other languages
English (en)
Russian (ru)
Other versions
EA201001197A1 (ru
Inventor
Стивен Стоукс
Николас Фолопп
Андреа Фиумана
Мартин Драйсдейл
Саймон Бедфорд
Пол Уэбб
Original Assignee
Вернэлис (Р&Д) Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0801090.2A external-priority patent/GB0801090D0/en
Priority claimed from GBGB0818695.9A external-priority patent/GB0818695D0/en
Application filed by Вернэлис (Р&Д) Лтд. filed Critical Вернэлис (Р&Д) Лтд.
Publication of EA201001197A1 publication Critical patent/EA201001197A1/ru
Publication of EA021464B1 publication Critical patent/EA021464B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EA201001197A 2008-01-22 2009-01-20 Производные индол-пиридона, обладающие ингибиторной активностью в отношении киназы 1, содержащая их фармацевтическая композиция и их применение EA021464B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0801090.2A GB0801090D0 (en) 2008-01-22 2008-01-22 New chemical compounds
GBGB0818695.9A GB0818695D0 (en) 2008-10-11 2008-10-11 New chemical compounds
PCT/GB2009/000149 WO2009093012A1 (en) 2008-01-22 2009-01-20 Indolyl- pyridone derivatives having checkpoint kinase 1 inhibitory activity

Publications (2)

Publication Number Publication Date
EA201001197A1 EA201001197A1 (ru) 2011-04-29
EA021464B1 true EA021464B1 (ru) 2015-06-30

Family

ID=40377594

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201001197A EA021464B1 (ru) 2008-01-22 2009-01-20 Производные индол-пиридона, обладающие ингибиторной активностью в отношении киназы 1, содержащая их фармацевтическая композиция и их применение

Country Status (17)

Country Link
US (5) US8916591B2 (enExample)
EP (1) EP2294065B1 (enExample)
JP (1) JP5386508B2 (enExample)
CN (1) CN101970424B (enExample)
AU (1) AU2009207478B2 (enExample)
BR (1) BRPI0906495B8 (enExample)
CA (1) CA2712959C (enExample)
DK (1) DK2294065T3 (enExample)
EA (1) EA021464B1 (enExample)
ES (1) ES2461799T3 (enExample)
IL (1) IL206808A (enExample)
MX (1) MX2010007525A (enExample)
NZ (1) NZ586756A (enExample)
PL (1) PL2294065T3 (enExample)
PT (1) PT2294065E (enExample)
WO (1) WO2009093012A1 (enExample)
ZA (1) ZA201005210B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916591B2 (en) 2008-01-22 2014-12-23 Vernalis (R&D) Ltd Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity
GB0912499D0 (en) * 2009-07-18 2009-08-26 Vernalis R&D Ltd Indopyl-pyridone derivatives
KR101464060B1 (ko) 2010-04-07 2014-11-20 에프. 호프만-라 로슈 아게 피라졸-4-일-헤테로사이클릴-카복사마이드 화합물 및 사용 방법
EP2463289A1 (en) * 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
WO2013045461A1 (en) 2011-09-27 2013-04-04 F. Hoffmann-La Roche Ag Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
GB201201566D0 (en) 2012-01-30 2012-03-14 Vernalis R&D Ltd New chemical compounds
EP3024456A4 (en) 2013-07-26 2017-04-12 Update Pharma Inc. Combinatorial methods to improve the therapeutic benefit of bisantrene
JP6704398B2 (ja) * 2015-01-28 2020-06-03 バイエル ファーマ アクチエンゲゼルシャフト 4H−ピロロ[3,2−c]ピリジン−4−オン誘導体
SG11202005700SA (en) * 2017-12-19 2020-07-29 Bristol Myers Squibb Co Amide substituted indole compounds useful as tlr inhibitors
KR20210038911A (ko) * 2018-07-24 2021-04-08 에피자임, 인코포레이티드 Smarca2 길항제로서 유용한 피리딘-2-온 화합물
US10280721B1 (en) 2018-07-27 2019-05-07 Upwing Energy, LLC Artificial lift
US10787873B2 (en) 2018-07-27 2020-09-29 Upwing Energy, LLC Recirculation isolator for artificial lift and method of use
US10370947B1 (en) * 2018-07-27 2019-08-06 Upwing Energy, LLC Artificial lift
US10253606B1 (en) 2018-07-27 2019-04-09 Upwing Energy, LLC Artificial lift
CA3109891A1 (en) * 2018-08-24 2020-02-27 Nanjing Transthera Biosciences Co., Ltd. Quinoline derivative inhibitor: tam, ntrk, and csf1r kinases
US11686161B2 (en) 2018-12-28 2023-06-27 Upwing Energy, Inc. System and method of transferring power within a wellbore
WO2021057782A1 (zh) * 2019-09-24 2021-04-01 南京药捷安康生物科技有限公司 杂环衍生物及其用途
JP2025523514A (ja) * 2022-06-24 2025-07-23 エナラーレ セラピューティクス インコーポレイテッド 神経性換気不全の処置方法
CN115594634B (zh) * 2022-10-26 2024-10-01 浙江工业大学 一种连续化制备4-硝基吡唑的新工艺

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002079192A1 (en) * 2001-03-28 2002-10-10 Bristol-Myers Squibb Company Novel tyrosine kinase inhibitors
WO2006134318A1 (en) * 2005-06-11 2006-12-21 Vernalis R & D Limited Pyrazole-substituted benzimidazole derivatives for use in the treatment of cancer and autoimmune disorders
WO2008025526A1 (en) * 2006-08-31 2008-03-06 F. Hoffmann-La Roche Ag Indole derivatives, their manufacture and use as pharmaceutical agents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0213562A (pt) 2001-10-26 2004-08-31 Aventis Pharma Inc Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna
US20050256157A1 (en) * 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
EP1633694A4 (en) 2003-06-05 2007-03-14 Merck & Co Inc SUBSTITUTED INDOLE AND METHOD FOR THE PRODUCTION OF SUBSTITUTED INDOLE
TWI372050B (en) * 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
CA2600914A1 (en) * 2005-01-28 2007-07-26 Mark E. Fraley Inhibitors of checkpoint kinases
JP2009543770A (ja) * 2006-07-14 2009-12-10 アステックス・セラピューティクス・リミテッド Cdk及びgskの阻害のためのピラゾール誘導体の組合せ剤
US8916591B2 (en) 2008-01-22 2014-12-23 Vernalis (R&D) Ltd Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity
BRPI1012203A2 (pt) * 2009-05-15 2016-04-05 Novartis Ag derivados de 5-piridin-3-il-1,3-di-hidro-indol-2-ona e seu uso como moduladores da aldosterona sintase e/ou da cyp11b1

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002079192A1 (en) * 2001-03-28 2002-10-10 Bristol-Myers Squibb Company Novel tyrosine kinase inhibitors
WO2006134318A1 (en) * 2005-06-11 2006-12-21 Vernalis R & D Limited Pyrazole-substituted benzimidazole derivatives for use in the treatment of cancer and autoimmune disorders
WO2008025526A1 (en) * 2006-08-31 2008-03-06 F. Hoffmann-La Roche Ag Indole derivatives, their manufacture and use as pharmaceutical agents

Also Published As

Publication number Publication date
EA201001197A1 (ru) 2011-04-29
BRPI0906495B8 (pt) 2021-05-25
US8916591B2 (en) 2014-12-23
EP2294065B1 (en) 2014-03-19
DK2294065T3 (da) 2014-04-28
CN101970424B (zh) 2013-06-12
IL206808A (en) 2015-08-31
US20170298043A1 (en) 2017-10-19
PL2294065T3 (pl) 2014-11-28
US20200361905A1 (en) 2020-11-19
BRPI0906495A8 (pt) 2015-10-06
CN101970424A (zh) 2011-02-09
PT2294065E (pt) 2014-05-15
EP2294065A1 (en) 2011-03-16
ES2461799T3 (es) 2014-05-21
WO2009093012A1 (en) 2009-07-30
CA2712959C (en) 2015-06-23
BRPI0906495A2 (pt) 2015-07-14
CA2712959A1 (en) 2009-07-30
AU2009207478A1 (en) 2009-07-30
US20110021498A1 (en) 2011-01-27
US10696652B2 (en) 2020-06-30
IL206808A0 (en) 2010-12-30
US20180244652A1 (en) 2018-08-30
NZ586756A (en) 2012-04-27
ZA201005210B (en) 2011-03-30
BRPI0906495B1 (pt) 2020-11-10
US20150099736A1 (en) 2015-04-09
JP5386508B2 (ja) 2014-01-15
AU2009207478B2 (en) 2013-11-21
MX2010007525A (es) 2010-08-18
JP2011510055A (ja) 2011-03-31
US9604975B2 (en) 2017-03-28

Similar Documents

Publication Publication Date Title
EA021464B1 (ru) Производные индол-пиридона, обладающие ингибиторной активностью в отношении киназы 1, содержащая их фармацевтическая композиция и их применение
EP0844877B1 (en) Use of oxido-squalene cyclase inhibitors to lower blood cholesterol
JP4183193B2 (ja) 含窒素芳香環誘導体
EP2601185B1 (en) Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents
TWI706939B (zh) 新穎二取代1,2,4-三化合物
BR112020014992A2 (pt) Inibidores de oxazina monoacilglicerol lipase (magl)
BR112014029851B1 (pt) Composto, inibidores da atividade da enzima ros1 quinase e da enzima ntrk quinase, composição farmacêutica, agente antitumor, agente terapêutico para um tumor, agente para tratamento de um tumor, e uso do referido composto
PT2727918T (pt) Compostos e composições como inibidores de proteína quinase
BRPI0720635A2 (pt) Compostos orgânicos e seus usos
US20130085161A1 (en) Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
CN102482259B (zh) 作为nk3受体拮抗剂的吡咯烷衍生物
JP2011522855A (ja) Nk3受容体アンタゴニストとしてのピロリジンエーテル誘導体
JP2017171619A (ja) 新規インドール誘導体及びこれを含有する医薬
CN114981270A (zh) Mll1抑制剂和抗癌剂
KR101372743B1 (ko) Nk3 수용체 길항제로서 피페리딘 유도체
CN103819476A (zh) 吡咯酮并吡唑类化合物及其作为药物的用途
CN120677159A (zh) 作为irak3的配体定向降解剂的经取代的基于咪唑的化合物

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM